JP2015505831A5 - - Google Patents

Download PDF

Info

Publication number
JP2015505831A5
JP2015505831A5 JP2014544964A JP2014544964A JP2015505831A5 JP 2015505831 A5 JP2015505831 A5 JP 2015505831A5 JP 2014544964 A JP2014544964 A JP 2014544964A JP 2014544964 A JP2014544964 A JP 2014544964A JP 2015505831 A5 JP2015505831 A5 JP 2015505831A5
Authority
JP
Japan
Prior art keywords
mutant
leukocidin
subunit
seq
subunit polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014544964A
Other languages
English (en)
Japanese (ja)
Other versions
JP6325452B2 (ja
JP2015505831A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/067483 external-priority patent/WO2013082558A1/en
Publication of JP2015505831A publication Critical patent/JP2015505831A/ja
Publication of JP2015505831A5 publication Critical patent/JP2015505831A5/ja
Application granted granted Critical
Publication of JP6325452B2 publication Critical patent/JP6325452B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014544964A 2011-12-02 2012-11-30 パントンバレンタインロイコシジン(pvl)由来ポリペプチドを含む免疫原性組成物 Active JP6325452B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161566234P 2011-12-02 2011-12-02
US61/566,234 2011-12-02
PCT/US2012/067483 WO2013082558A1 (en) 2011-12-02 2012-11-30 Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides

Publications (3)

Publication Number Publication Date
JP2015505831A JP2015505831A (ja) 2015-02-26
JP2015505831A5 true JP2015505831A5 (enExample) 2016-01-28
JP6325452B2 JP6325452B2 (ja) 2018-05-16

Family

ID=48536149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014544964A Active JP6325452B2 (ja) 2011-12-02 2012-11-30 パントンバレンタインロイコシジン(pvl)由来ポリペプチドを含む免疫原性組成物

Country Status (13)

Country Link
US (1) US10023848B2 (enExample)
EP (1) EP2785368B1 (enExample)
JP (1) JP6325452B2 (enExample)
KR (1) KR101999299B1 (enExample)
AU (1) AU2012345645B2 (enExample)
CA (1) CA2857666C (enExample)
DK (1) DK2785368T3 (enExample)
ES (1) ES2728445T3 (enExample)
HR (1) HRP20190907T1 (enExample)
LT (1) LT2785368T (enExample)
RS (1) RS58919B1 (enExample)
SI (1) SI2785368T1 (enExample)
WO (1) WO2013082558A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2857666C (en) 2011-12-02 2020-08-11 Integrated Biotherapeutics, Inc. Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides
HK1223978A1 (zh) 2013-06-18 2017-08-11 New York University 参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素:新型治疗靶点
US9815872B2 (en) 2013-06-19 2017-11-14 Integrated Biotherapeutics, Inc. Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20160244511A1 (en) * 2013-10-17 2016-08-25 Arsanis Biosciences Gmbh Cross-reactive staphylococcus aureus antibody sequences
WO2017026301A1 (ja) * 2015-08-10 2017-02-16 株式会社微生物化学研究所 黄色ブドウ球菌不活化菌体とロイコシジンを混合したワクチン
CN107224575B (zh) * 2017-03-06 2018-11-09 浙江海隆生物科技有限公司 奶牛金黄色葡萄球菌乳房炎亚单位疫苗的组合物及其制备方法和应用
CN110996993B (zh) 2017-07-27 2024-05-31 Ab疫苗公司 包含源自超抗原类毒素的融合肽的免疫原性组合物
WO2025085539A1 (en) * 2023-10-16 2025-04-24 The Trustees Of Columbia University In The City Of New York Engineered bacteria for cellular barrier maintenance and protection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US20100158871A1 (en) 1999-08-30 2010-06-24 David Stephen Terman Sickled erythrocytes with antitumor molecules induce tumoricidal effects
US20050008633A1 (en) 2003-05-19 2005-01-13 Advanced Inhalation Research Inc. Chemical and physical modulators of bioavailability of inhaled compositions
MX2007015758A (es) * 2005-06-13 2008-02-22 Nabi Biopharmaceuticals Uso de leucocidina de panton-valentine para tratar y prevenir infecciones por estafilococos.
US7754225B2 (en) 2006-07-20 2010-07-13 Glaxosmithkline Biologicals S.A. Method of protecting against staphylococcal infection
AU2007310738B2 (en) * 2006-10-18 2013-07-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for in vitro diagnosis of PVL-producing Staphylococcus aureus
CA2857666C (en) 2011-12-02 2020-08-11 Integrated Biotherapeutics, Inc. Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides

Similar Documents

Publication Publication Date Title
JP2015505831A5 (enExample)
CA2873272C (en) Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
DK3110438T3 (en) USPA2 PROTEIN CONSTRUCTS AND APPLICATIONS THEREOF
JP7072921B2 (ja) A群レンサ球菌ワクチン
KR20210088535A (ko) 폐렴구균 융합 단백질 백신
Jing et al. Oligomerization of IC43 resulted in improved immunogenicity and protective efficacy against Pseudomonas aeruginosa lung infection
EP3833387A1 (en) Compositions and methods for preventing and treating virus infection
ES2367128T3 (es) Procedimiento para preparar una variante del antígeno protector de superficie de erysipelothrix rhusiopathiae en e. coli.
US10933126B2 (en) Clostridium difficile immunogenic compositions and methods of use
US20250281591A1 (en) Staphylococcus aureus vaccine compositions
JP2021505525A (ja) A群レンサ球菌に対する免疫原性ペプチド
WO2022067255A2 (en) Variant staphylococcus aureus luka and lukb polypeptides and vaccine compositions
TW201347770A (zh) 致熱原性外毒素b胜肽疫苗
CN117355328A (zh) 金黄色葡萄球菌疫苗组合物
US20190276502A1 (en) Fusion polypeptides derived from staphylococcus aureus antigens
EP3535281A1 (en) Fusion polypeptides